Abstract Library

#4079 Temporal increase in Ki-67 index in patients with pancreatic neuroendocrine tumors (PanNETs): Frequency, prognostic impact, and causal factors

Introduction: PanNETs show intra-tumor heterogeneity, notably regarding Ki-67 index which is a major prognostic biomarker. Temporal heterogeneity and its prognostic impact have been poorly explored so far.

Conference:

Presenting Author: Bourdeleau-Guerry P

Authors: Bourdeleau-Guerry P, Pokossy-Epée J, Hentic O, Couvelard A, Ruszniewski P,

Keywords: neuroendocrine tumor, Ki-67 index, tumor grade, temporal evolution, molecular evolution, biologic evolution,

#4011 Differences in the microRNA expression of G1 and G2 pancreatic neuroendocrine tumors

Introduction: Targeted testing of microRNAs implicated in the biology of pancreatic neuroendocrine tumors (PNET) was performed via RT-QPCR to uncover differentially expressed microRNAs that could be used as diagnostic markers characteristic for tumor grade.

Conference:

Presenting Author:

Authors: Nyirő G, Szeredás B, Vékony B, Borka K, Zalatnai A,

Keywords: miRNA expression, PNET G1 and G2, RT-QPCR, hsa-miR-130b-3p, hsa-miR-194-5p, hsa-miR-96-5p, hsa-miR-106b, FFPE tissue,

#3961 Enhancer heterogeneity of lung carcinoids reveals sensitivity to FGF signaling inhibition

Introduction: Well-differentiated low grade lung carcinoids are histo-pathologically classified as typical and atypical, but each subtype is still heterogenous both at the molecular level and its clinical manifestation. Therefore, the treatment of these patients is challenging. The two main challenges are the lack of effective drug treatments and the lack of reliable biomarkers to guide management since the disease in patients with the same tumor grade/stage often has different clinical courses. The genetic, epigenetic, and developmental programs that drive lung carcinoids remain obscure, limiting our abilities to suggest new biomarkers and drug targets.

Conference:

Presenting Author: Drier Y

Authors: Davis E, Avniel-Polak S, Hecht M, Grozinsky-Glasberg S, Drier Y,

Keywords: FGF Signaling, Lung carcinoids, Enhancers,

#3866 Treatment efficacy in 212 metastatic small intestinal neuroendocrine tumor grade 2 patients

Introduction: Small intestinal neuroendocrine tumors (Si-NET) are frequently studied as a single entity, irrespective of their grade, which is known to influence prognosis.

Conference:

Presenting Author: Papantoniou D

Authors: Papantoniou D, Grönberg M, Thiis-Evensen E, Sorbye H, Landerholm K,

Keywords: small intestinal neuroendocrine tumor, grade 2, somatostatin analogues, PRRT, Ki-67, somatostatin-receptor negative,

#3838 Subgroup analysis of ORR and PFS of the SEQTOR study (GETNE 1206) – Everolimus followed by Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs

Introduction: Previous global results of ORR and PFS1 have been presented. The best treatment (Tx) sequence between STZ-5FU and everolimus (EVE) in patients (pts) with advanced and progressive panNETs is not yet well established.

Conference:

Presenting Author: Salazar R

Authors: Capdevila J, Tafuto S, Krogh M, Teulé A, Garcia-Carbonero R,

Keywords: panNET, everolimus, STZ-5FU,